Nifty Healthcare Index Corporate Filings & Announcements

Latest corporate announcements and filings from Nifty Healthcare Index on BSE

Load latest

Lupin Ltd.

30 Apr 2025

2057.10

-1.84%

Company Update

Lupin Ltd - 500257 - Updates On Transfer Of Company''s API R&D Division And Over-The-Counter Consumer …

BSE India

Update on transfer of Company''s API R&D Division and Over-the -Counter Consumer Healthcare Business on Slump sale basis.

pdf

Syngene International Ltd.

29 Apr 2025

627.95

-0.96%

Company Update

Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the details of the meeting to be held with the Analyst/Institutional Investor.

pdf

Biocon Ltd.

29 Apr 2025

318.90

-0.90%

Company Update

Biocon Ltd - 532523 - Redemption Of Commercial Papers

BSE India

Redemption of Commercial Papers

pdf

Lupin Ltd.

29 Apr 2025

2057.10

-1.84%

Board Meeting

Lupin Ltd - 500257 - Board Meeting Intimation for Considering And Taking On Record Audited Standalone …

BSE India

Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 ,inter alia, to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025 and recommend dividend, if any.

pdf

Cipla Ltd.

29 Apr 2025

1525.60

-1.58%

Corp. Note

Cipla Ltd - 500087 - Format of the Initial Disclosure to be made by an entity …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyCipla Ltd 2CIN NO.L24239MH1935PLC002380 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AAA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Rajendra Chopra Designation: Company Secretary and Compliance Officer EmailId: cosecretary@cipla.com Name of the Chief Financial Officer: Ashish Adukia Designation: Global Chief Financial Officer EmailId: cosecretary@cipla.com Date: 29/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Glenmark Pharmaceuticals Ltd.

29 Apr 2025

1375.00

-0.45%

Corp. Note

Glenmark Pharmaceuticals Ltd - 532296 - Rumour verification - Regulation 30(11)

BSE India

Clarification/Confirmation on news item appearing in "Media/Publication"

pdf

Syngene International Ltd.

28 Apr 2025

627.95

-0.96%

Earnings Call

Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Intimation of Earnings call transcript for Q4 FY2025.

pdf

Syngene International Ltd.

28 Apr 2025

627.95

-0.96%

Company Update

Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the details of the meeting to be held with the Analyst/Institutional Investor.

pdf